Morgan Stanley Upgrades Arrowhead Pharma to Overweight, Raises Price Target to $100

Benzinga Newsdesk www.benzinga.com Positive 91.2%

Neg 0% Neu 0% Pos 91.2%

Morgan Stanley analyst Michael Ulz upgrades Arrowhead Pharma (NASDAQ:ARWR) from Equal-Weight to Overweight and raises the price target from $78 to $100.